drugset / Trial / NCT03093831
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 2
Terminated
5 enrolled
National Cancer Centre, Singapore
Samsung Medical Center · collabSingapore General Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of Ibrutinib in predominantly Asian patients with relapsed or refractory marginal zone lymphoma.
Timeline
- Start
- 2016-07-08
- Primary completion
- 2020-07-17
- Completion
- 2020-07-17
Outcome
Outcome not reported
Stopped (Enrollment): “Study did not meet the objectives and terminated early on 17 Jul 2020 due to poor recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 140 mg | Oral |
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |